42例恶性肿瘤并发乙型肝炎患者替比夫定治疗效果观察

Analysis on the telbivudine treatment effect of 42 cases of malignant tumor complicated with chronic hepatitis B virus infection

目的 探讨恶性肿瘤并发慢性乙型病毒性肝炎患者应用替比夫定治疗的临床疗效.方法 纳入42例恶性肿瘤并发慢性乙型病毒性肝炎患者,根据是否应用替比夫定进行抗病毒治疗分为试验组及对照组,试验组患者在进行放化疗前1w开始应用替比夫定进行抗病毒治疗,对照组患者仅进行放化疗治疗,不行抗病毒治疗.两组患者中的部分患者辅以护肝治疗,但均未使用降酶药物.结果 治疗后发现试验组患者HBV DNA的下降以及血清ALT（AST）的改善率均优于对照组患者,两组间差异有统计学意义（P＜0.01）.结论 对恶性肿瘤合并慢性乙型病毒性肝炎患者使用替比夫定抗病毒治疗能够有效的预防放化疗后所引起的乙肝病毒激活.

Objective To investigate the clinical effect of telbivudine treatment application in malignant tumor patients with chronic hepatitis B.Methods A total of 42 cases of malignant tumor complicated with chronic hepatitis B patients were included in the study.The objects were divided into experimental group and control group according to whether using telbivudine antiviral treatment.The patients in experimental group began to use telbivudine antiviral chemotherapy treatment a week before radiotherapy and chemotherapy.The patients in the control group only accepted radiotherapy.Some patients in these two groups accepted guard liver therapy, but the drop enzyme drug was not used.Results HBV DNA decreased and serum ALT （AST） improvement rate were better than the patients in the control group after treatment.There was statistical significant difference between the two groups （P 〈 0.01）.Conclusions The treatment can cause effective preventive chemotherapy after use telbivudine antiviral hepatitis B virus activation in chronic hepatitis B patients of malignant tumor.